Figure 4.

Protein expression of RHAMM on the TMAs was analyzed for the association with clinical parameters such as tumor stage (T stage; A), lymph node status (N stage; B), and PSA (C) categorized using the mean PSA level as cutoff value. P values were calculated based on the Mann-Whitney U test. (A) There is a strong association between RHAMM protein expression and tumor stage defined as T2 and T3. Pathologic T3 tumors known to have worse outcome have a significant lower RHAMM expression (P = .01). (B) Lymph node-positive patients have a significant lower protein expression in the primaries compared with patients without lymph node metastases at the time of radical prostatectomy (P < .0001). (C) Patients with high PSA levels, known as an independent predictor for worse outcome, have a significantly lower protein expression of RHAMM (P < .001).